Epidemiology of occult hepatitis B and C in Africa: A systematic review and meta-analysis.
Africa
Occult hepatitis B
Occult hepatitis C
Prevalence
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
09
2022
revised:
04
11
2022
accepted:
08
11
2022
pubmed:
18
11
2022
medline:
7
12
2022
entrez:
17
11
2022
Statut:
ppublish
Résumé
Occult hepatitis B (OBI) and C (OCI) infections lead to hepatic crises including cases of liver cirrhosis and even hepatocellular carcinoma (HCC). OBI and OCI also pose a significant problem of their transmissibility. This study aimed to assess the overall prevalence of OBI and OCI in the African continent, a region highly endemic for classical hepatitis B and C viruses. For this systematic review and meta-analysis, we searched: PubMed, Web of Science, African Journal Online and African Index Medicus for published studies on the prevalence of OBI and OCI in Africa. Study selection and data extraction were performed by at least two independent investigators. Heterogeneity (I²) was assessed using the χ² test on the Cochran Q statistic and H parameters. Sources of heterogeneity were explored by subgroup analyses. This study was registered in PROSPERO, with reference number CRD42021252772. We obtained 157 prevalence data for this meta-analysis, from 134 studies for OBI prevalence; 23 studies on OCI prevalence, and a single study on the OBI case fatality rate. The overall estimate for the prevalence of OBI was 14.8% [95% CI = 12.2-17.7] among 18579 participants. The prevalence of seronegative OBI and seropositive OBI was 7.4% [95% CI = 3.8-11.8] and 20.0% [95% CI = 15.3-25.1] respectively. The overall estimate for the prevalence of OCI was 10.7% [95% CI = 6.6-15.4] among 2865 participants. The pooled prevalence of seronegative OCI was estimated at 10.7% [95%CI = 4.8-18.3] and that of seropositive OCI at 14.4% [95%CI = 5.2-22.1]. In Sub-group analysis, patients with malignancies, chronic hepatitis C, and hemodialysis had a higher OCI prevalence. While those with malignancies, liver disorders, and HIV positive registered highest OBI prevalence. This review shows a high prevalence of OBI and OCI in Africa, with variable prevalence between countries and population groups.
Sections du résumé
BACKGROUND
BACKGROUND
Occult hepatitis B (OBI) and C (OCI) infections lead to hepatic crises including cases of liver cirrhosis and even hepatocellular carcinoma (HCC). OBI and OCI also pose a significant problem of their transmissibility. This study aimed to assess the overall prevalence of OBI and OCI in the African continent, a region highly endemic for classical hepatitis B and C viruses.
METHODS
METHODS
For this systematic review and meta-analysis, we searched: PubMed, Web of Science, African Journal Online and African Index Medicus for published studies on the prevalence of OBI and OCI in Africa. Study selection and data extraction were performed by at least two independent investigators. Heterogeneity (I²) was assessed using the χ² test on the Cochran Q statistic and H parameters. Sources of heterogeneity were explored by subgroup analyses. This study was registered in PROSPERO, with reference number CRD42021252772.
RESULTS
RESULTS
We obtained 157 prevalence data for this meta-analysis, from 134 studies for OBI prevalence; 23 studies on OCI prevalence, and a single study on the OBI case fatality rate. The overall estimate for the prevalence of OBI was 14.8% [95% CI = 12.2-17.7] among 18579 participants. The prevalence of seronegative OBI and seropositive OBI was 7.4% [95% CI = 3.8-11.8] and 20.0% [95% CI = 15.3-25.1] respectively. The overall estimate for the prevalence of OCI was 10.7% [95% CI = 6.6-15.4] among 2865 participants. The pooled prevalence of seronegative OCI was estimated at 10.7% [95%CI = 4.8-18.3] and that of seropositive OCI at 14.4% [95%CI = 5.2-22.1]. In Sub-group analysis, patients with malignancies, chronic hepatitis C, and hemodialysis had a higher OCI prevalence. While those with malignancies, liver disorders, and HIV positive registered highest OBI prevalence.
CONCLUSION
CONCLUSIONS
This review shows a high prevalence of OBI and OCI in Africa, with variable prevalence between countries and population groups.
Identifiants
pubmed: 36395668
pii: S1876-0341(22)00303-3
doi: 10.1016/j.jiph.2022.11.008
pmc: PMC7613883
mid: EMS157310
pii:
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1436-1445Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Competing interests None.
Références
J Med Virol. 2010 Sep;82(9):1569-75
pubmed: 20648611
Infez Med. 2018 Sep 1;26(3):237-243
pubmed: 30246766
Mediterr J Hematol Infect Dis. 2018 Jan 01;10(1):e2018007
pubmed: 29326804
J Egypt Public Health Assoc. 2013 Apr;88(1):14-8
pubmed: 23528527
J Int AIDS Soc. 2014 May 22;17:18871
pubmed: 24855985
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Clin Exp Med. 2022 Jan 23;:
pubmed: 35066710
Virol J. 2015 Sep 30;12:153
pubmed: 26420301
J Clin Transl Hepatol. 2017 Dec 28;5(4):319-326
pubmed: 29226098
Sci Rep. 2018 Jan 26;8(1):1661
pubmed: 29374178
J Med Virol. 2016 Apr;88(4):674-80
pubmed: 26334654
Res Synth Methods. 2016 Mar;7(1):55-79
pubmed: 26332144
Antivir Ther. 2010;15(7):1029-34
pubmed: 21041918
J Viral Hepat. 2022 May;29(5):317-329
pubmed: 35253969
World J Gastroenterol. 2015 Nov 14;21(42):11941-53
pubmed: 26576083
Virol J. 2011 Mar 03;8:90
pubmed: 21371325
J Gastroenterol Hepatol. 2008 Sep;23(9):1426-30
pubmed: 18853999
World J Hepatol. 2017 Mar 28;9(9):477-486
pubmed: 28396718
J Hepatol. 2007 Jan;46(1):160-70
pubmed: 17112622
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Int J Infect Dis. 2014 Dec;29:65-70
pubmed: 25449238
Transfus Med. 2008 Feb;18(1):55-61
pubmed: 18279193
J Med Virol. 2009 Mar;81(3):406-12
pubmed: 19152393
J Viral Hepat. 2020 Apr;27(4):415-427
pubmed: 31834645
Virol J. 2020 Nov 13;17(1):176
pubmed: 33187530
J Viral Hepat. 2014 Mar;21(3):153-62
pubmed: 24438677
PLoS One. 2020 May 28;15(5):e0233727
pubmed: 32463824
Infect Drug Resist. 2022 Feb 24;15:619-630
pubmed: 35241914
J Infect Public Health. 2016 Jul-Aug;9(4):452-7
pubmed: 26778093
Ther Adv Infect Dis. 2019 May 23;6:2049936119851464
pubmed: 31205689
J Clin Virol. 2006 Jan;35(1):14-20
pubmed: 15916918
Int J Infect Dis. 2009 Jul;13(4):488-92
pubmed: 19081280
Scand J Gastroenterol. 2020 Aug;55(8):963-969
pubmed: 32649843
Egypt J Immunol. 2017 Jan;24(1):131-142
pubmed: 29120585
J Med Virol. 2016 Aug;88(8):1388-93
pubmed: 26743014
Electron Physician. 2015 Dec 20;7(8):1619-25
pubmed: 26816589
Arch Virol. 2017 Jan;162(1):63-69
pubmed: 27665588
Hum Vaccin Immunother. 2014;10(8):2336-41
pubmed: 25424940
J Clin Epidemiol. 2012 Sep;65(9):934-9
pubmed: 22742910
PLoS One. 2016 Jan 14;11(1):e0143869
pubmed: 26764909
J Hepatol. 2014 Mar;60(3):508-14
pubmed: 24211737
Carcinogenesis. 2012 Jun;33(6):1219-24
pubmed: 22759751
Diagnostics (Basel). 2022 Apr 17;12(4):
pubmed: 35454063
PLoS One. 2022 May 31;17(5):e0269250
pubmed: 35639675
Infect Dis (Lond). 2022 Dec;54(12):881-896
pubmed: 36047593
Pan Afr Med J. 2013;14:44
pubmed: 23560127
Mem Inst Oswaldo Cruz. 2020 Sep 23;115:e200006
pubmed: 32997000
Eur J Gastroenterol Hepatol. 2021 Jul 1;33(7):1009-1014
pubmed: 33731578
AIDS Res Ther. 2017 Mar 8;14(1):11
pubmed: 28270215
J Clin Virol. 2015 Feb;63:12-7
pubmed: 25600597
Egypt J Immunol. 2018 Jan;25(1):45-56
pubmed: 30242997
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82
pubmed: 23892239
Int J Infect Dis. 2012 Apr;16(4):e268-72
pubmed: 22305987
J Viral Hepat. 2015 Feb;22(2):103-11
pubmed: 24754376
J Infect Dis. 2022 Sep 13;226(5):862-870
pubmed: 34160616
Vaccine. 2016 Jul 19;34(33):3835-9
pubmed: 27265453
J Trop Med. 2014;2014:796121
pubmed: 24868208
World J Hepatol. 2013 Feb 27;5(2):64-73
pubmed: 23646231
PLoS One. 2018 Jan 9;13(1):e0190592
pubmed: 29315352
Liver Int. 2009 Apr;29(4):518-24
pubmed: 19192168
Virol J. 2010 Nov 17;7:324
pubmed: 21083926
Environ Sci Pollut Res Int. 2018 Feb;25(6):5459-5464
pubmed: 29214477
Arch Virol. 2020 Jan;165(1):33-42
pubmed: 31630275
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420961202
pubmed: 33045856
SAGE Open Med. 2022 Jan 30;10:20503121211072748
pubmed: 35127096
Rev Soc Bras Med Trop. 2015 May-Jun;48(3):258-64
pubmed: 26108002
Arch Inst Pasteur Tunis. 2010;87(1-2):17-24
pubmed: 21604457
World J Hepatol. 2021 Feb 27;13(2):242-260
pubmed: 33708353
PLoS One. 2021 Jan 6;16(1):e0244947
pubmed: 33406137
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Med Mal Infect. 2018 May;48(3):175-179
pubmed: 29249466
Eur J Gastroenterol Hepatol. 2019 Jun;31(6):716-722
pubmed: 30870221
Infection. 2015 Jun;43(3):307-14
pubmed: 25665956
Eur J Intern Med. 2011 Apr;22(2):187-90
pubmed: 21402251
World J Methodol. 2022 May 20;12(3):179-190
pubmed: 35721241
Int J Mol Sci. 2022 Jun 10;23(12):
pubmed: 35742931
Hepat Res Treat. 2012;2012:429784
pubmed: 23304473
East Mediterr Health J. 2017 Jul 16;23(5):329-334
pubmed: 28730585
Iran Red Crescent Med J. 2015 Nov 29;17(11):e34181
pubmed: 26734487
JGH Open. 2020 Aug 26;4(5):800-807
pubmed: 33102748
Sci Rep. 2020 Dec 17;10(1):22182
pubmed: 33335238
PLoS One. 2018 Jan 10;13(1):e0190775
pubmed: 29320552
J Clin Transl Hepatol. 2018 Jun 28;6(2):155-160
pubmed: 29951360
J Clin Microbiol. 2011 Jan;49(1):298-306
pubmed: 21048009
Open Forum Infect Dis. 2017 Sep 13;4(4):ofx195
pubmed: 29062862
Lancet. 1988 Dec 3;2(8623):1273-6
pubmed: 2904005
Immunol Invest. 2010 Jan;39(3):284-91
pubmed: 20380524
J Infect Public Health. 2017 Nov - Dec;10(6):761-765
pubmed: 28196636
J Gastroenterol. 2009;44(4):359-64
pubmed: 19271112
Curr Opin Virol. 2017 Jun;24:31-37
pubmed: 28419938
Arab J Gastroenterol. 2018 Sep;19(3):101-105
pubmed: 30245116
Clin Lab. 2012;58(9-10):1057-61
pubmed: 23163124
Liver Int. 2014 Jul;34(6):e144-50
pubmed: 24502524
Gut. 2005 May;54(5):682-5
pubmed: 15831916
S Afr Med J. 2012 Feb 23;102(3 Pt 1):157-62
pubmed: 22380911
Pan Afr Med J. 2021 Jul 06;39:175
pubmed: 34584601
Genes (Basel). 2018 May 17;9(5):
pubmed: 29772814
J Med Virol. 2015 Feb;87(2):213-21
pubmed: 25156907
Transfusion. 2009 Apr;49(4):757-64
pubmed: 19171000
J Hepatol. 2019 Aug;71(2):397-408
pubmed: 31004683
Pathogens. 2021 Dec 17;10(12):
pubmed: 34959588
PLoS One. 2015 Jul 06;10(7):e0131912
pubmed: 26148052
Niger Med J. 2019 Jan-Feb;60(1):22-26
pubmed: 31413431
Virologie (Montrouge). 2008 Apr 1;12(2):87-94
pubmed: 36131428
East Mediterr Health J. 2014 Mar 13;20(2):130-8
pubmed: 24945562
S Afr Med J. 2013 May;103(5):330-3
pubmed: 23971125
World J Hepatol. 2012 Jul 27;4(7):218-23
pubmed: 22855697
Int J Infect Dis. 2020 Mar;92:13-18
pubmed: 31863879
Virol J. 2016 May 05;13:76
pubmed: 27150469
Hepat Mon. 2012 Apr;12(4):253-8
pubmed: 22690232
J Egypt Public Health Assoc. 2013 Apr;88(1):8-13
pubmed: 23528526
J Med Virol. 2015 Mar;87(3):424-7
pubmed: 25185940
Arch Basic Appl Med. 2018 Feb;6(1):87-93
pubmed: 29963604
Virol J. 2022 Mar 24;19(1):53
pubmed: 35331278
J Infect Public Health. 2015 Nov-Dec;8(6):562-9
pubmed: 26026236
PLoS One. 2020 Nov 19;15(11):e0242577
pubmed: 33211768
J Med Virol. 2009 Nov;81(11):1860-8
pubmed: 19774687
Egypt J Immunol. 2017 Jan;24(1):37-48
pubmed: 29120576
Int J Infect Dis. 2020 Aug;97:126-130
pubmed: 32497807
PLoS One. 2012;7(10):e45750
pubmed: 23049685
J Pediatr Hematol Oncol. 2021 Jan;43(1):e45-e50
pubmed: 32769568
Infect Drug Resist. 2019 Jan 22;12:273-279
pubmed: 30774394
Intervirology. 2009;52(3):123-31
pubmed: 19468235
Virologie (Montrouge). 2005 Aug 1;9(4):331
pubmed: 34679301
Int J Oncol. 2013 Apr;42(4):1459-65
pubmed: 23404231
World J Gastroenterol. 2012 Jun 21;18(23):2887-94
pubmed: 22736911
J Med Virol. 2015 Mar;87(3):388-400
pubmed: 25164924
J Infect Dev Ctries. 2012 Apr 13;6(4):340-6
pubmed: 22505444
Curr HIV Res. 2016;14(2):165-71
pubmed: 26419862
Blood Transfus. 2019 Nov;17(6):403-408
pubmed: 31846605
J Med Virol. 2011 Jun;83(6):929-34
pubmed: 21503902